A  

Milnacipran is a serotonin-norepinephrine re-uptake inhibitor approved for fibromyalgia and depression, with no role in treating osteoporosis, whereas teriparatide (PTH analog), strontium ranelate, and denosumab are all established pharmacologic options for osteoporosis management [Neer 2001, PMID 11120882; Meunier 2004, PMID 15576617; Cummings 2009, PMID 19858174].